New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:49 EDTACT, FURXActavis completes acquisition of Furiex
Actavis (ACT) announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals (FURX) in an all-cash transaction valued at approximately $1.1B, and up to approximately $360M in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's product, as a controlled drug following approval. In connection with the close of the Furiex acquisition, Actavis further announced that it has closed the transaction related to the sale of Furiex's royalties on alogliptin and Priligy to Royalty Pharma for approximately $415M.
News For ACT;FURX From The Last 14 Days
Check below for free stories on ACT;FURX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use